NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
about
sameAs
HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinomaDynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situCancer/testis antigens: an expanding family of targets for cancer immunotherapyTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence.Evolutionary diversification of SPANX-N sperm protein gene structure and expressionMelanoma: tumor microenvironment and new treatments.An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients.Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factorsA pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with responseIncreased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.Broadening the repertoire of melanoma-associated T-cell epitopes.Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinomaAn evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification.Immunohistochemistry in melanocytic proliferative lesions.Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Germ cell proteins in melanoma: prognosis, diagnosis, treatment, and theories on expression.Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients.New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues.Melanoma: a prototype of cancer-testis antigen-expressing malignancies.Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients.NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules
P2860
Q24315946-BD91DC91-929C-4279-A601-90191665A620Q24539022-4A4FDC07-4BCD-41C7-8525-1A720ADE92F3Q28204616-4D6274A8-1C98-4587-9E3C-F41391EC65B0Q28215652-3932BCEE-4A24-4A4A-A283-B61CE239A8F1Q29616128-302095B0-0E74-47D6-8F68-687ADE073312Q30411491-A67D531A-F11F-410E-B028-9362866838E8Q30445102-FD5231FD-B439-418E-824C-057F4CC1EC32Q33675676-D7F6AE87-18A7-486B-B99C-2D84B5AAEF3AQ34032518-869251AD-CB8B-49B3-9908-C77F2D91DBA7Q34111725-150B6270-2812-457C-9104-3B1A8B48FE2AQ35182795-62AB1692-3AA0-4BFC-9537-0F51BAA488E9Q35543740-805C582C-6445-48E7-BE1F-9240FF84712EQ35546276-4A770745-AC7C-481A-BCF0-53F3A713006AQ35740912-D303A9F5-CCF9-4AE2-8CFB-0004CAB16BC9Q35769842-414E619D-9865-411D-AF47-F679CA8C20ACQ35789880-A27A3B7B-3C1F-40BB-B0CC-06A56C7D69E2Q35798186-1E618190-020C-4140-83A0-21168D98B504Q36143956-13190932-82FC-457A-BE44-864BEE95C747Q36471827-8190A6FA-A2E4-4245-8031-B1308BFCF82FQ37737327-E43A3FE7-FC4B-44A6-A182-ED809997CE76Q38064856-F71BD9C5-8D7A-4341-AD52-BC8A8E35A5F1Q38403243-9B084F9D-BDB2-44E5-8571-1C6CABA521E5Q38445350-78A226E6-F6DB-4411-919B-A7D310BDF489Q40484689-D0B83648-AF2F-4FFE-AB69-3DEDC825438EQ50070352-E29235E4-3382-4140-AF35-9E0CDC450654Q52800577-952BE427-73EA-4FB9-9EFB-37926AE75E26Q54945263-281416E1-8A37-48B1-A847-9AB060F67CF9Q57805467-89FFB7E7-A1AF-45E4-8F48-0D93CA6FE1CF
P2860
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
description
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
scientific article (publication date: 15 June 2001)
@en
vedecký článok (publikovaný 2001/06/15)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/06/15)
@nl
наукова стаття, опублікована в червні 2001
@uk
مقالة علمية (نشرت في 15-6-2001)
@ar
name
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@ast
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@en
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@nl
type
label
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@ast
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@en
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@nl
prefLabel
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@ast
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@en
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@nl
P2093
P356
P1476
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
@en
P2093
P356
10.1006/JSRE.2001.6148
P407
P577
2001-06-15T00:00:00Z